Alcohol-Related Liver Disease

Most veteran with cirrhosis and coexisting alcohol-use disorder did not receive behavioral or pharmacotherapy treatment for alcohol use during 6 months of follow-up, according to data published in Hepatology.

Alcohol use was a significant risk factor for clinically defined nonalcoholic fatty liver disease due to association with alcohol use and liver fat, according to recently published data.

Data from a phase 2a clinical trial of DUR-928, an endogenous, small-molecule new chemical entity, for patients with alcoholic hepatitis demonstrated that the treatment led to greater reductions from baseline in bilirubin and MELD and improved Lille scores compared with a historical control group from a University of Louisville alcoholic hepatitis study, according to a company press release.

Use of an automated investigation algorithm known as intelligent liver function testing increased liver disease diagnoses and improved patient quality of care in a cost-effective manner, according to a study published in Journal of Hepatology.